Related Experiment Video
Updated: May 17, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Refractory pediatric actinic prurigo successfully treated with upadacitinib: A case report
Florence Morissette1, Jérome Coulombe2
1Dermatology Division, Department of Medicine, CHUM, University of Montreal, QC, Canada.
Insights
Actinic prurigo, a rare skin condition triggered by sunlight, often affects children. A novel treatment using upadacitinib, a janus kinase inhibitor, showed success in a refractory pediatric case.
Area of Science:
- Dermatology
- Immunology
- Photodermatology
Background:
- Actinic prurigo is a rare photodermatosis characterized by pruritic lesions on sun-exposed skin.
- It commonly affects children and is associated with cheilitis and conjunctivitis.
- The pathophysiology is believed to involve a type IV hypersensitivity reaction to ultraviolet radiation.
Observation:
- A 12-year-old boy presented with severe, treatment-resistant actinic prurigo.
- The patient experienced persistent pruritic papulonodules on sun-exposed areas.
Findings:
- The patient was treated with upadacitinib, a selective janus kinase (JAK) inhibitor.
- Upadacitinib demonstrated significant efficacy in resolving the refractory actinic prurigo symptoms.
Implications:
- This case highlights upadacitinib as a potential therapeutic option for refractory actinic prurigo.
- Targeting the JAK-STAT pathway may offer a new treatment strategy for this photodermatosis.
Abstract:
Actinic prurigo is a rare photodermatosis, usually occurring during childhood. Pruritic papulonodules on sun-exposed areas are frequently associated with cheilitis and conjunctivitis. The most widely accepted pathophysiology to date is a type IV hypersensitivity reaction triggered by ultraviolet radiation. This case report describes a 12-year-old boy suffering from refractory actinic prurigo, who was successfully treated with the janus kinase inhibitor upadacitinib.
